Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:MSCL)

Satellos Appoints Stephanie Brown to Board of Directors

Business Wire 7 days ago

Satellos Reports Q3 2024 Financial Results and Provides Clinical Update

Business Wire 8 days ago

Satellos to Participate in November 2024 Investor Conferences

Business Wire November 4, 2024

Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels

Business Wire October 1, 2024

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

Business Wire September 18, 2024

Satellos Announces Participation in September 2024 Investor Conferences

Business Wire September 5, 2024

Satellos Biosciences to advance DMD treatment to clinical trials

Jocelyn Aspa August 19, 2024

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Business Wire August 19, 2024

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

Business Wire August 12, 2024
View More News ››

Opinion & Analysis (TSX:MSCL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:MSCL)

Satellos Reports Q3 2024 Financial Results and Provides Clin

Breaking News: $MSCLF Satellos Reports Q3 2024 Financial Results and Provides Clinical Update- Completed enrollment for SAT-3247 in...
whytestocks - 7 days ago

RE:RE:Webinar Recap: $MSCL CEO Frank Gleeson and CFO Liz Williams

Rug pull on horizon. Up on no volume. Bad look.
BaddPitt - November 5, 2024

RE:Webinar Recap: $MSCL CEO Frank Gleeson and CFO Liz Williams

Satellos to Participate in November 2024 Investor Conferences
G1945V - November 4, 2024

Webinar Recap: $MSCL CEO Frank Gleeson and CFO Liz Williams

<< View Post To Watch Video >>
bmreed - October 7, 2024

Webinar $MSCL CEO Frank Gleeson Oct 3 @ 1PM ET / 10AM PT

Live Webinar - Satellos Bioscience (MSCL) CEO Frank Gleeson and CFO Elizabeth Williams Thursday, October 3rd at 1PM ET / 10AM PT Q...
bmreed - September 28, 2024

Filing to Commence a Phase 1 Clinical Trial

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247  
G1945V - July 11, 2024
View more Bullboard ››

Forsys Metals Corp

Forsys Metals Corp

Forsys Metals Corp. is a Canada-based uranium developer. The Company is engaged in the acquisition, exploration and ...
View More »